Abstract:The current 'fixed-dosage strategy' approach to medicine, means there is much inter-individual variation in drug response. Pharmacogenetics is the study of how inter-individual variations in the DNA sequence of specific genes affect drug responses. This article will highlight current pharmacogenetic knowledge on important drug metabolizing enzymes, drug transporters and drug targets to understand interindividual variability in drug clearance and responses in clinical practice and potential use in personalized medicine. Polymorphisms in the cytochrome P450 (CYP) family may have had the most impact on the fate of pharmaceutical drugs. CYP2D6, CYP2C19 and CYP2C9 gene polymorphisms and gene duplications account for the most frequent variations in phase I metabolism of drugs since nearly 80% of drugs in use today are metabolised by these enzymes. Approximately 5% of Europeans and 1% of Asians lack CYP2D6 activity, and these individuals are known as poor metabolizers. CYP2C9 is another clinically significant drug metabolising enzyme that demonstrates genetic variants. Studies into CYP2C9 polymorphism have highlighted the importance of the CYP2C9*2 and CYP2C9*3 alleles. Extensive polymorphism also occurs in a majority of Phase II drug metabolizing enzymes. One of the most important polymorphisms is thiopurine S-methyl transferases (TPMT) that catalyzes the S-methylation of thiopurine drugs. With respect to drug transport polymorphism, the most extensively studied drug transporter is P-glycoprotein (P-gp/MDR1), but the current data on the clinical impact is limited. Polymorphisms in drug transporters may change drug's distribution, excretion and response. Recent advances in molecular research have revealed many of the genes that encode drug targets demonstrate genetic polymorphism. These variations, in many cases, have altered the targets sensitivity to the specific drug molecule and thus have a profound effect on drug efficacy and toxicity. For example, the beta (2)-adrenoreceptor, which is encoded by the ADRB2 gene, illustrates a clinically significant genetic variation in drug targets. The variable number tandem repeat polymorphisms in serotonin transporter (SERT/SLC6A4) gene are associated with response to antidepressants. The distribution of the common variant alleles of genes that encode drug metabolizing enzymes, drug transporters and drug targets has been found to vary among different populations. The promise of pharmacogenetics lies in its potential to identify the right drug at the right dose for the right individual. Drugs with a narrow therapeutic index are thought to benefit more from pharmacogenetic studies. For example, warfarin serves as a good practical example of how pharmacogenetics can be utilized prior to commencement of therapy in order to achieve maximum efficacy and minimum toxicity. As such, pharmacogenetics has the potential to achieve optimal quality use of medicines, and to improve the efficacy and safety of both prospective and licensed drugs.

New Insights of CYP1A in Endogenous Metabolism: a Focus on Single Nucleotide Polymorphisms and Diseases

Identification and Functional Assessment of EightCYP3A4Allelic Variants39–46Detected in the Chinese Han Population

Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication

Advances in Human Cytochrome P450 and Personalized Medicine

Progress in relationship of cytochrome P450 1A2 genetic polymorphism,substance metabolism and carcinogenesis

[Heterogeneous expression of human CYP and its application in early stage of new drug research and development].

CYP-nsSNP: A Specialized Database Focused on Effect of Non-Synonymous SNPs on Function of CYPs

Progress in research of cytochrome P450 3A4 gene polymorphism

Computational Analysis of Functional Single Nucleotide Polymorphisms Associated with the CYP11B2 Gene

CYP1A inhibitors: Recent progress, current challenges, and future perspectives

A bioinformatics approach for the phenotype prediction of nonsynonymous single nucleotide polymorphisms in human cytochromes P450.

Identification and in vitro functional assessment of 10 CYP2C9 variants found in Chinese Han subjects

Han Chinese specific cytochrome P450 polymorphisms and their impact on the metabolism of anti-hypertensive drugs with adrenoreceptor blocking properties

Insights into CYP2B6-mediated drug-drug interactions

Clinical Pharmacogenetics and Potential Application in Personalized Medicine.

In silico screening and analysis of nonsynonymous SNPs in human CYP1A2 to assess possible associations with pathogenicity and cancer susceptibility

Identification and Functional Assessment of Eight CYP3A4 Allelic Variants 39-46 Detected in the Chinese Han Population

Identification of the Effects of Pathogenic Genetic Variations of Human CYP2C9 and CYP2D6: An In Silico Approach

Functional characterization of the chlorzoxazone 6-hydroxylation activity of human cytochrome P450 2E1 allelic variants in Han Chinese

Evaluation of the Effects of Cytochrome P450 Nonsynonymous Single-Nucleotide Polymorphisms on Tanshinol Borneol Ester Metabolism and Inhibition Potential

A comprehensive overview of common polymorphic variants that cause missense mutations in human CYPs and UGTs